Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 5 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Corcept Therapeutics Incorporated has 8 pending office actions in Biotechnology & Pharmaceuticals. Those actions are spread among 8 distinct examiners and 5 distinct art units. The examiner count matches the action count, while the lower art unit count indicates that some art units handle matters assigned to different examiners.
TRAN, ERIC is the busiest examiner, with 1 pending matter. No examiner carries more than that figure in the supplied data, so prosecution management should emphasize consistent claim support and issue tracking across the separate examiner assignments.
The distribution across 5 art units creates a coordination need for counsel. Responses can be organized around recurring technology and claim themes, while still preserving examiner-specific arguments where the records require them.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (25%) |
| Double-patenting only | 3 (38%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, ERIC | 1 | 69.7% | +19.4% |
| SEAMAN, D MARGARET M | 1 | 76.7% | +8.0% |
| DAHLIN, HEATHER RAQUEL | 1 | 41.9% | +46.0% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 75.7% | +36.8% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.8% |
| MARTIN, KEVIN STEPHEN | 1 | 77.0% | +20.7% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.3% |
| RODRIGUEZ, RAYNA B | 1 | 33.4% | +19.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18676126 | SULFONE METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18779659 | Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor Modulators | DAHLIN, HEATHER RAQUEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18920639 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | TRAN, ERIC | — |
| 18779659 | Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor Modulators | DAHLIN, HEATHER RAQUEL | — |
| 18764781 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | HEASLEY, MEGHAN CHRISTINE | — |
| 18676126 | SULFONE METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | WILLIS, DOUGLAS M | — |
| 18670160 | METHODS FOR TREATING ADRENAL GLAND TUMORS | MARTIN, KEVIN STEPHEN | — |
| 18584163 | METHODS OF PREPARING INTERMEDIATES OF HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | MCDOWELL, BRIAN E | — |
| 18444342 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | RODRIGUEZ, RAYNA B | — |
| Art Unit | Apps |
|---|---|
| 1624 | 3 |
| 1629 | 2 |
| 1625 | 1 |
| 1626 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18920639 | METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | TRAN, ERIC | 1629 | DP | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18908611 | POLYMORPHS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | SEAMAN, D MARGARET M | 1625 | DP | Non-Final OA | — | Pending | Oct 07, 2024 |
| 18779659 | Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor Modulators | DAHLIN, HEATHER RAQUEL | 1629 | §102§103§112Other | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18764781 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | HEASLEY, MEGHAN CHRISTINE | 1626 | DP | Non-Final OA | — | Pending | Jul 05, 2024 |
| 18676126 | SULFONE METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | — | Pending | May 28, 2024 |
| 18670160 | METHODS FOR TREATING ADRENAL GLAND TUMORS | MARTIN, KEVIN STEPHEN | 1624 | §103§112DP | Non-Final OA | — | Pending | May 21, 2024 |
| 18584163 | METHODS OF PREPARING INTERMEDIATES OF HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | MCDOWELL, BRIAN E | 1624 | §112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18444342 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | RODRIGUEZ, RAYNA B | 1628 | §102§103§112DP | Non-Final OA | — | Pending | Feb 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCorcept Therapeutics Incorporated has 8 pending office actions as of November 2026, spread across 5 art units and 8 examiners.
Eric Tran has the most, with 1 of Corcept Therapeutics Incorporated's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.